skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the use of fibrates: focus on bezafibrate

Review

(2380) Views  (703) Full article downloads

Authors: Ilan Goldenberg, Michal Benderly, Uri Goldbourt

Published Date May 2008 Volume 2008:4(1) Pages 131 - 141
DOI: http://dx.doi.org/10.2147/VHRM.S1434

Ilan Goldenberg1, Michal Benderly2, Uri Goldbourt2,3

1Heart Institute and 2Neufeld Cardiac Research Institute, Sheba Medical Center Tel Hashomer, Israel; 3Division of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Abstract: Low-density lipoprotein-cholesterol (LDL-C) is a well established coronary heart disease (CHD) risk factor. However, the ability of this metabolic risk factor alone to identify individuals at risk for future CHD events is limited. The raised triglycerides-low high-density lipoprotein-cholesterol (HDL-C) dyslipidemia was shown to be an important cardiovascular risk factor independently of LDL-C levels. Fibric acid derivatives (fibrates) have been used in clinical practice for more than 2 decades as a class of agents known to decrease triglyceride levels while substantially increasing HDL-C levels. Through peroxisome proliferator-activated α-receptors, fibrates have a significant impact on the synthesis of several apolipoproteins and enzymes of lipoprotein metabolism as well as on the expression of several genes involved in fibrinolysis and inflammation. Data from recent primary and secondary prevention clinical trials demonstrate the efficacy of fibrate therapy in patients with the raised triglycerides-low HDL-C dyslipidemia. This review summarizes current data regarding mechanism of action and the metbolic effects of fibrates, as well as results from major clinical trials on the efficacy of this mode of lipid lowering therapy. In addition, recent data from subgroup analyses of the Bezafibrate Infarction Prevention trial, demonstrating several important metabolic and long-term cardiovascular effects of bezafibrate therapy, are detailed.

Keywords: fibrates, high-density lipoprotein-cholsterol, metabolic syndrome, peroxisome proliferator-activated α-receptors, cardiac events








Readers of this article also read:

Risk stratification for arrhythmic death in an emergency department cohort: a new method of nonlinear PD2i analysis of the ECG
Pupillography of automated swinging flashlight test in amblyopia
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Update on the clinical use of the low-molecular-weight heparin, parnaparin
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG
The utility of troponin measurement to detect myocardial infarction: review of the current findings
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
Erratum
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University